Human stem cell-derived renal cells and in vitro platforms for ne | 55652
Journal of Clinical Toxicology

Journal of Clinical Toxicology
Open Access

ISSN: 2161-0495

+44 7868 792050

Human stem cell-derived renal cells and in vitro platforms for nephrotoxicity prediction

9th Euro-Global Summit on Toxicology and Applied Pharmacology

June 22-24, 2017 Paris, France

Jacqueline Chuah, Sijing Xiong, Yao Li, Peng Huang, Rensheng Deng, Kim Guan Eng, Lit-Hsin Loo, Jackie Y Ying and Daniele Zink

Institute of Bioengineering and Nanotechnology, Singapore
Bioinformatics Institute, Singapore

Scientific Tracks Abstracts: J Clin Toxicol

Abstract :

There is an increasing demand for alternative methods for the evaluation of compound toxicity in humans. Accepted alternative methods for the prediction of toxicities for human internal organs, such as liver and kidney, are not available. We have developed the first pre-validated platforms for the prediction of compound-induced nephrotoxicity in humans. These methods include the first high-throughput platform for the accurate prediction of nephrotoxicity, as well as the first and only predictive stem cell-based methods. Our stem cell-based methods employ a rapid and robust one-step protocol for the differentiation of human induced pluripotent stem cells (iPSC) into renal proximal tubular cell (PTC)-like cells. PTC is a major target for compound-induced toxicity in the kidney due to their roles in compound transport and metabolism. IPSC-derived PTC-like cells have a purity of >90% after only 8 days of differentiation (Kandasamy et al., 2015). They can be directly applied for compound screening, as no cell purification is required. A method for the prediction of nephrotoxicity has been developed by combining use of iPSC-derived PTC-like cells with machine learning methods. This method has been pre-validated with 30 compounds and has a test balanced accuracy of 87%. Furthermore, the underlying mechanisms of drug-induced cellular injury could also be correctly identified. PTC-like cells are also suitable for applications in our high-throughput platform, which combines high-content imaging of renal cells with automated phenotypic profiling and machine learning methods. This automated platform has been pre-validated with 44 compounds and has a test balanced accuracy ranging between 82%-89%, depending on the human renal cell type used. Based on these technologies we are currently developing a portfolio of platforms for the prediction of various organ-specific toxicities. In addition, we have established an organ-on-chip platform for repeated dose testing. This robust platform is based on simple and disposable chips and may be suitable for predicting quantitative parameters of the human dose response, such as no observed adverse effect levels.

Biography :

Jacqueline Chuah received her BSc in Biological Sciences from the Nanyang Technological University, Singapore. In 2013, she joined Dr. Daniele Zink’s team at the Institute of Bioengineering and Nanotechnology of the Agency for Science, Technology and Research, Singapore. Her work is focused on developing stem cell-based assays to predict kidney toxicity.